findmyKOL

Aaron Farberg, MD

Enriched profile

Chief Medical Officer, Bare Dermatology (Dallas, Texas) · University of North Texas Health Science Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Rockwall, TX · South Central · United StatesSpecialtyMOHS-Micrographic SurgeryFocusNonmelanoma Skin Cancer Studies+4
Active KOLfindmyKOL type: NationalLatest publication2020Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Aaron Farberg is Chief Medical Officer, Bare Dermatology (Dallas, Texas) at University of North Texas Health Science Center. OpenAlex indexes 176 publications with 2,272 citations (h-index 26); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 19 Oct 2026

Overview

Updated 19 Oct 2026

Aaron Farberg, MD, is Chief Medical Officer, Bare Dermatology (Dallas, Texas) at University of North Texas Health Science Center. The public record shows 176 publications with 2,272 citations (h-index 26), centered on Nonmelanoma Skin Cancer Studies, Head and Neck Cancer Studies, Cutaneous Melanoma Detection and Management. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 41 companies.

  • Most recent indexed publication: 2020 · Brain structure & function
  • Top research focus: Nonmelanoma Skin Cancer Studies
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 41 companies

Generated from the cited public record · current as of 19 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Melanoma1 trialAtopic Dermatitis / Eczema1 trialSurgical Wound1 trialCarcinoma, Squamous Cell1 trialBasal Cell Carcinoma1 trialChronic Urticaria1 trialUrticaria1 trialBreast CancerHead & Neck Cancer

Research focus

OpenAlex concept fingerprint
Nonmelanoma Skin Cancer StudiesHead and Neck Cancer StudiesCutaneous Melanoma Detection and ManagementDermatology and Skin DiseasesBreast Cancer Treatment Studies

Drugs & molecules

across trials, industry payments and publications
Odomzogeneric · SonidegibClinical trials—Industry payments82Publications1Tremfyageneric · GuselkumabClinical trials—Industry payments223Publications—Cibinqogeneric · AbrocitinibClinical trials—Industry payments121Publications—Libtayogeneric · CemiplimabClinical trials—Industry payments104Publications—Opzelurageneric · RuxolitinibClinical trials—Industry payments89Publications—Ilumyageneric · TildrakizumabClinical trials—Industry payments75Publications—Bimzelxgeneric · BimekizumabClinical trials—Industry payments72Publications—Skyrizigeneric · RisankizumabClinical trials—Industry payments62Publications—Dupixentgeneric · DupilumabClinical trials—Industry payments60Publications—Cosentyxgeneric · SecukinumabClinical trials—Industry payments57Publications—Spevigogeneric · SpesolimabClinical trials—Industry payments46Publications—Sotyktugeneric · DeucravacitinibClinical trials—Industry payments44Publications—

Works with

trial sponsors and companies reporting payments
Janssen Biotech, Inc.Clinical trials—Industry payments217Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments187Pfizer Inc.Clinical trials—Industry payments148Galderma Laboratories, L.P.Clinical trials—Industry payments127Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments121Abbvie Inc.Clinical trials—Industry payments99Incyte CorporationClinical trials—Industry payments89Novartis Pharmaceuticals CorporationClinical trials—Industry payments86UCB, Inc.Clinical trials—Industry payments81Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments72E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments68LEO Pharma Inc.Clinical trials—Industry payments48Ortho Dermatologics, a division of Bausch Health US, LLCClinical trials—Industry payments39Genzyme CorporationClinical trials—Industry payments37Amgen Inc.Clinical trials—Industry payments36Almirall LLCClinical trials—Industry payments26Arcutis Biotherapeutics, Inc.Clinical trials—Industry payments22Dermavant Sciences, Inc.Clinical trials—Industry payments22Lilly USA, LLCClinical trials—Industry payments19Botanix SB IncClinical trials—Industry payments14Janssen Scientific Affairs, LLCClinical trials—Industry payments14Boehringer Ingelheim International GmbHClinical trials—Industry payments12Mayne Pharma Commercial LLCClinical trials—Industry payments10Verrica Pharmaceuticals Inc.Clinical trials—Industry payments10Biofrontera Inc.Clinical trials—Industry payments7Kerecis LimitedClinical trials—Industry payments4STRATA Skin Sciences, Inc.Clinical trials—Industry payments4Eli Lilly and CompanyClinical trials—Industry payments3Journey Medical CorporationClinical trials—Industry payments2MIMEDX Group, Inc.Clinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
176publications

Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.

2,272citations

Total citations across indexed works.

26h-index

Hirsch index (OpenAlex). i10-index 57.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
41companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Industry payments

Updated 19 Oct 2026

41 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 19 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 19 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Darrell S. Rigel41Matthew S. Goldberg27Steven R. Buchman18Alex M. Glazer18Alexis Donneys18Jennifer J. Siegel17Sagar Satish Deshpande15Catherine N. Tchanque‐Fossuo15Sarah J. Kurley13Richard R. Winkelmann13Alison L. Fitzgerald13Gary Goldenberg10Nicholas A. Squittieri10Hooman Khorasani10Ryan M. Svoboda10Ally-Khan B. Somani9Ann P. Quick9Laura A. Monson9Mark Lebwohl9Anesh Prasai9Sherrif F. Ibrahim9Michael Robert Migden8Sarah T. Arron7Danielle P. Dubin7Matthew J. Lin6Elizabeth R. Razdolsky6Jonathan I. Silverberg6Peter W. Hashim6Alexander David Guminski6Lary C. Walker6Peter Lio6Graham H Litchman6Olga Zolochevska6Rebecca F. Rosen6Robert W. Cook6Reinhard Dummer6John Y. M. Koo6Todd M. Preuss5Justin W. Marson5Kelli L. Ahmed5

Online presence

Updated 19 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/aaron-farberg-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 19 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Lead Editor

    Non-Invasive Technologies for the Diagnosis and Management of Skin Cancer

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →livderm.org ↗
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →livderm.org ↗

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.